Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
| Revenue (TTM) | $2.86B |
| Gross Profit (TTM) | $1.79B |
| EBITDA | $666.60M |
| Operating Margin | 28.20% |
| Return on Equity | 16.40% |
| Return on Assets | 9.53% |
| Revenue/Share (TTM) | $28.75 |
| Book Value | $32.50 |
| Price-to-Book | 4.06 |
| Price-to-Sales (TTM) | 4.67 |
| EV/Revenue | 4.245 |
| EV/EBITDA | 18.21 |
| Quarterly Earnings Growth (YoY) | 47.70% |
| Quarterly Revenue Growth (YoY) | 28.30% |
| Shares Outstanding | $100.36M |
| Float | $99.07M |
| % Insiders | 1.11% |
| % Institutions | 101.82% |
Volatility is currently expanding